Literature DB >> 18470273

Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history.

Erik Pasin, David Y Josephson, Anirban P Mitra, Richard J Cote, John P Stein.   

Abstract

Superficial "non-muscle-invasive" bladder tumors represent a heterogeneous group of cancers, including those that are (1) papillary in nature and limited to the mucosa, (2) high grade and flat and confined to the epithelium, and (3) invasive into the submucosa, or lamina propria. The goal of treatment is 2-fold: (1) to reduce tumor recurrence and the subsequent need for additional therapies and the morbidity associated with these treatments and (2) to prevent tumor progression and the subsequent need for more aggressive therapy. This update reviews important contemporary concepts in the etiology, molecular mechanisms, classification, and natural history of superficial bladder cancer.

Entities:  

Keywords:  Bladder neoplasms; Genitourinary tumors; Molecular mechanisms; Non-muscle-invasive tumor; Transitional cell carcinoma

Year:  2008        PMID: 18470273      PMCID: PMC2312342     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  128 in total

1.  Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

Authors:  Tomonori Habuchi; Michael Marberger; Michael J Droller; George P Hemstreet; H Barton Grossman; Jack A Schalken; Bernd J Schmitz-Dräger; William M Murphy; Aldo V Bono; Peter Goebell; Robert H Getzenberg; Stefan H Hautmann; Edward Messing; Yves Fradet; Vinata B Lokeshwar
Journal:  Urology       Date:  2005-12       Impact factor: 2.649

Review 2.  Natural history of superficial bladder cancer. Prognostic features and long-term disease course.

Authors:  N M Heney
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

3.  Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups.

Authors:  F Millán-Rodríguez; G Chéchile-Toniolo; J Salvador-Bayarri; J Huguet-Pérez; J Vicente-Rodríguez
Journal:  J Urol       Date:  2000-10       Impact factor: 7.450

4.  Tobacco use, occupation, coffee, various nutrients, and bladder cancer.

Authors:  G R Howe; J D Burch; A B Miller; G M Cook; J Esteve; B Morrison; P Gordon; L W Chambers; G Fodor; G M Winsor
Journal:  J Natl Cancer Inst       Date:  1980-04       Impact factor: 13.506

5.  Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).

Authors:  M K Parmar; L S Freedman; T B Hargreave; D A Tolley
Journal:  J Urol       Date:  1989-08       Impact factor: 7.450

6.  FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

Authors:  Adel H Jebar; Carolyn D Hurst; Darren C Tomlinson; Colin Johnston; Claire F Taylor; Margaret A Knowles
Journal:  Oncogene       Date:  2005-08-04       Impact factor: 9.867

7.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

8.  DBCCR1 mediates death in cultured bladder tumor cells.

Authors:  Kate O Wright; Edward M Messing; Jay E Reeder
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

9.  Concepts in causality: chemically induced human urinary bladder cancer.

Authors:  G M Lower
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

10.  The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks.

Authors:  E M Messing; T B Young; V B Hunt; S E Emoto; J M Wehbie
Journal:  J Urol       Date:  1987-05       Impact factor: 7.450

View more
  78 in total

Review 1.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

2.  Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.

Authors:  Haris Zahoor; Maria C Mir; Pedro C Barata; Andrew J Stephenson; Steven C Campbell; Amr Fergany; Robert Dreicer; Jorge A Garcia
Journal:  Invest New Drugs       Date:  2019-06-24       Impact factor: 3.850

3.  Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records.

Authors:  Peter J Bostrom; Paul J Toren; Hao Xi; Raymond Chow; Tran Truong; Justin Liu; Kelly Lane; Laura Legere; Anjum Chagpar; Alexandre R Zlotta; Antonio Finelli; Neil E Fleshner; Ethan D Grober; Michael A S Jewett
Journal:  J Am Med Inform Assoc       Date:  2011-08-04       Impact factor: 4.497

4.  E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer.

Authors:  Chao Cheng; Frederick S Varn; Carmen J Marsit
Journal:  Mol Cancer Res       Date:  2015-06-01       Impact factor: 5.852

Review 5.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

Review 6.  The Rho GTPase signalling pathway in urothelial carcinoma.

Authors:  Solomon L Woldu; Ryan C Hutchinson; Laura-Maria Krabbe; Oner Sanli; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

7.  Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma.

Authors:  Shuzhe Yang; Xiaohou Wu; Chunli Luo; Cuicui Pan; Jun Pu
Journal:  World J Urol       Date:  2010-07-01       Impact factor: 4.226

Review 8.  Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.

Authors:  Robert T Jones; Kenneth M Felsenstein; Dan Theodorescu
Journal:  Urol Clin North Am       Date:  2015-10-31       Impact factor: 2.241

9.  Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance.

Authors:  José I López; Javier C Angulo
Journal:  Int Urol Nephrol       Date:  2009-03-12       Impact factor: 2.370

10.  Genetic susceptibility to distinct bladder cancer subphenotypes.

Authors:  Lin T Guey; Montserrat García-Closas; Cristiane Murta-Nascimento; Josep Lloreta; Laia Palencia; Manolis Kogevinas; Nathaniel Rothman; Gemma Vellalta; M Luz Calle; Gaëlle Marenne; Adonina Tardón; Alfredo Carrato; Reina García-Closas; Consol Serra; Debra T Silverman; Stephen Chanock; Francisco X Real; Núria Malats
Journal:  Eur Urol       Date:  2009-08-12       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.